Shares in Australian biotech Mesoblast (ASX: MSB) dropped by a fifth on Tuesday, after the firm announced the DREAM-HF Phase III trial missed its primary endpoint.
Mesoblast, a leader in allogeneic cellular medicines for inflammatory diseases, is testing rexlemestrocel-L as an option for advanced chronic heart failure.
While the study produced a significant reduction in the pre-specified endpoint of cardiac death, there was no reduction in recurrent non-fatal decompensated heart failure events.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze